Podcasts about tme

helpful grand prix eventbrite kudos sounding lms getting close fairyland lookout mountain orgplease tme laura walker tennessee waltz

Play Episode Listen Later Jan 7, 2025 52:44

Winter Hendrickson joins me this week on TME to talk about her journey through infertility, adoption, and the miracle births of two biological children! Winter's story is incredible, encouraging, and a beautiful episode to start out the new year. You can find Winter on Instagram Looking to save money on quality, bulk foods? Shop ⁠⁠⁠⁠⁠⁠⁠Azure Standard⁠⁠⁠⁠⁠⁠⁠ Watch on ⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠ Visit ⁠⁠⁠⁠⁠⁠⁠The Motherhood Experience⁠⁠⁠⁠⁠⁠⁠ Website Follow us on ⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠ Find us on ⁠⁠⁠⁠⁠⁠⁠Facebook

one way tme

190.大佬攒局、内部创业、大厂分拆，盘点互联网血泪往事

乱翻书

Play Episode Listen Later Dec 17, 2024 108:21

【本期嘉宾】程苓峰、庄明浩、阑夕程苓峰（科技自媒体）庄明浩（「屠龙之术」主理人）阑夕（知名IT人）主播：潘乱（「乱翻书」主理人）【本场聊天缘起】本场是临时攒的局，起因是程苓峰关于极越汽车的行业锐评文章《不要攒局》【时间线】01:12 程苓峰，为什么会写《不要攒局》这篇文章？05:07 明浩，熊猫TV应该也算王思聪跟 360 的攒局项目？06:41 “5点起床赶早班机，我老婆问我公司到底是谁的？”07:42 任旭阳找龚宇来做爱奇艺，跟为极越找夏一平是相同路数09:42 龚宇在爱奇艺之前的90年代已经独立创办过焦点房产网，后来搜狐高峰时候做 SVP+COO，但夏一平去极越才是他第一次做CEO10:32 十年前王健林跟马云打赌，后来万达拉上腾讯和百度成立了腾百万公司，对标阿里12:39 百度初心不是造车，是推广阿波罗系统，但华为也是鸿蒙智行，为什么结果不一样？13:43 华为不是从零到一再造车企，而是先从帮助弱势车企入局17:29 阿里跟上汽曾经也攒过个局，斑马智行17:45 九九房也是SIG攒局拉来张一鸣做CEO，但张一鸣从九九房跑路跟 Kimi 团队有何异同？19:53 朱啸虎是想告诉市场，是张宇彤出了问题，不是金沙江管理团队出了问题21:20 新一波的创业公司对CEO的角色的要求太高了23:13 顺势而为已经过时了，现在要的是平地起风云24:57 大黄蜂、爱屋吉屋、阿维塔、瑞幸27:41 宿华和程一笑也是投资人攒在一起的，但快手是先有了程一笑完成从零到一29:09 沈博阳从糯米到赤兔30:24 美团不喜欢用外企背景高管32:25 郑志昊从MSN到QQ，发现校招来的都是微软不要的学生34:28 今天的大厂，就是十年前的外企34:53 2015年百度航母计划硕果仅存的成功案例：作业帮38:08 2010年前后百度的中间页战略39:39 任旭阳给百度的5个建议42:15 任旭阳非常早看到推荐算法的威力，创办了一点资讯，但最早自己没下场42:56 OpenAI最早也是攒局项目，一群人为了对抗 Google45:08 玉伯对大厂内部创业前后不同的看法往期推荐：71.对话玉伯&镜同：语雀的前世今生，跟钉钉和支付宝是什么关系？160.对话玉伯：字节是我在阿里的第16年，今天是Last Day49:01 大厂的资源、能力也是个诅咒49:21 夏一平会被员工围堵要求缴社保，内部创业失败了不会50:01 叮当和灵犀互娱，樊路远和阿里大文娱，到底谁才是真正的三国志战略版的拥有者？52:36 龚宇和李彦宏，谁对做成爱奇艺功劳更大？54:18 张小龙和马化腾，谁对做成微信功劳更大？56:30 为什么说俞军不是贴吧之父？59:55 雷军当年做的米聊是对标 Facebook，跟微信压根不是一类产品62:47 马化腾的股份设计64:49 张一鸣通过收购创业公司的方式来做招聘68:24 腾讯和字节确定的扩张性是什么？74:12 阅文、TME和度小满，裂土封侯还是发配边疆？81:57 再说 Musical.ly 收购案，没有你对我很重要84:51 关于孙忠怀保下腾讯视频的不同视角观察96:08 宅心仁厚 vs 刻薄寡恩96:42 京东分拆的吃相太过难看103:45 张一鸣说创办头条不是为了变成腾讯员工，但张一鸣很希望别人来字节上班106:50 我们这场讨论定的标准太高了【开场&结尾音乐】开场音乐：李小龙 - 好久不见（电视剧《武林外传》片头曲）结尾音乐：虞霞/李小龙 - 侠客行（电视剧《武林外传》片尾曲TV Verison）【相关推荐】1、阑夕对本次直播的总结（全文约5千字，原文见链接）：m.okjike.com2、玉伯收听本场直播的感想（原文见链接）：3、往期推荐，两期不同时间采访玉伯的播客71.对话玉伯&镜同：语雀的前世今生，跟钉钉和支付宝是什么关系？（2022年8月）160.对话玉伯：字节是我在阿里的第16年，今天是Last Day（2024年5月）【关于「乱翻书」】「乱翻书」是一档关注商业、科技和互联网的圆桌对话节目。关心How和Why，以及少有人注意到的What。内容主要方向是科技考古、行业观察和前沿思考，研究公司的兴衰循环，希望能够为你带来信息增量。「乱翻书」主理人是潘乱，代表作品有《腾讯没有梦想》、字节跳动/快手早期关键节点的系列特写。【关于主播】即刻/视频号/B站/抖音：潘乱公众号/播客：乱翻书【图】▲直播截图微信公众号：乱翻书视频号：潘乱商业合作：联系微信 tongxing717本期编辑：怀杭

tv ceo musical openai last day kimi sig tme

2024 Dec - The Lookout Mountain Grand Prix 2025 is getting close - Plan Now

the Mountain Echo

Play Episode Listen Later Dec 15, 2024 36:01

tME sits down with longtime mountain resident Mr Chandler Rennick to hear all about the upcoming car race on Lookout Mountain which will 100%, directly benefit the LMS and Fairyland, elementary schools.*********************************************************Many thanks for his time and a job very well done to Chandler. This is a fantastic episode for parents with children who may welcome a fun, challenging activity for these colder winter months - and the great news as Chandler explains is the ease and structure of how it all works. Thanks in large part to his team/ board and community members, this event is planned as a win-win for all involved - see if you know any of these mountain folks - bet you do.Listen in and hear how to learn more, how to participate and when and where the fun will occur. Sounding like a seasoned radio personality, Chandler effortlessly eases the listener through the entire event from all aspects - alpha to omega. There are some steps you will want to click on and easily complete and the cost is very doable - this event is about supporting our community schools and this simply offers a smart and fun way to do that support. Kudos to Chandler and his talented and supportive wife, Jamie Ann who was instrumental in the event ever happening in the first place. Thank you, Jamie Ann.Helpful info:Chandler Rennick - CRennick1@gmailwww.EventBrite.comSpread the word! Find us at ...theMountainEcho.orgPlease "Like" and 'subscribe' for notification of new episodes on your media player's podcast menu. Also, on regular, full length, non-bonus episodes, many thanks for closing music featuring the Dismembered Tennesseans and vocals by the amazing Laura Walker singing Tennessee Waltz. Opening fiddle music played by the late Mr. Fletcher Bright.

85. Nine Perfect Strangers & One Creepy Neighbour

THE MUMS EDIT.

Play Episode Listen Later Nov 26, 2024 38:41

Hold onto your coffee cups (or wine glasses), ladies - this week's episode is a rollercoaster of opinions, updates, and overshares! Steph dishes all about her Nine Perfect Strangers-style wellness retreat IRL - did she find zen or just a whole lot of weird? We also discuss...Our very candid thoughts on GPsThe latest on Ziggy's eye journey (spoiler: he's still the cutest)The ultimate relationship boundary: number 2s in front of your partnerLil's new fear that'll make you rethink nature itselfRen's creepy neighbor (is it time for a restraining order?)Get ready to laugh, cringe, and nod along - this episode's got all the juicy bits!We love you! TME xxxx

creepy irl neighbours ziggy nine perfect strangers tme

Henssler Money Talks — November 2, 2024

Money Talks Radio Show - Atlanta, GA

Play Episode Listen Later Nov 2, 2024 46:04

Text us your financial questions!Henssler Money Talks — November 2, 2024Season 38, Episode 44This week on "Money Talks," Director of Research, Nick Antonucci, CVA, CEPA, is joined by Managing Associate Melanie Wells, CFP®, and Arun Gupta, Esq., estate planning attorney with Reeves Law P.C. The radio hosts recapped the highs and lows in this week's market landscape, touching on Consumer Sentiment and Consumer Confidence and the preliminary estimate for third-quarter GDP. Arun joins the show to discuss a situation where a son has been named the executor of his mother's estate. Arun explores the order in which the process usually follows and the duties of an executor. Rounding out the show, the experts answer listener's questions on catch-up contributions, Warner Music Group, and Tencent Music Entertainment. Timestamps and Chapters00:00: Market Roundup: Oct. 28 – Nov 1, 202422:23: Case Study: What to Know as an Executor of an Estate 37:04: Q&A Time: Catch-Up Contributions, Warner Music Group, and Tencent Music EntertainmentFollow Henssler: Facebook: https://www.facebook.com/HensslerFinancial/ YouTube: https://www.youtube.com/c/HensslerFinancial LinkedIn: https://www.linkedin.com/company/henssler-financial/ Instagram: https://www.instagram.com/hensslerfinancial/ TikTok: https://www.tiktok.com/@hensslerfinancial?lang=en X: https://www.x.com/hensslergroup “Money Talks” is brought to you by Henssler Financial. Sign up for the Money Talks Newsletter: https://www.henssler.com/newsletters/

director tiktok research housing estate gdp cfp esq rounding trusts money talks probate cepa consumer confidence warner music group executor cva consumer sentiment tme wmg arun gupta henssler durable goods tencent music entertainment

TME Weekly - Week 3

FantasySharks Weekly

Play Episode Listen Later Sep 19, 2024 44:59

TME breakdown. Classic football is back!

classic tme

059 Finding Life After Unsurmountable Loss: Brenda Coombs

loss finding life coombs tme

Play Episode Listen Later Sep 17, 2024 83:18

Brenda Coombs' story, while one of substantial tragedy and trauma, is one of encouragement, endurance, and ultimate victory. Brenda's first husband took his life, and five years later, two of her children died in a car accident. This is one of, if not *the* most powerful TME episodes I've had the honor of recording to date. Looking to save money on quality, bulk foods? Shop ⁠Azure Standard⁠ Watch on ⁠YouTube⁠ Visit ⁠The Motherhood Experience⁠ Website Follow us on ⁠Instagram⁠

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death

Oncotarget

Play Episode Listen Later Aug 5, 2024 2:34

BUFFALO, NY- August 5, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 12, 2024, entitled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.” In this study, researchers Chantal L. Duurland, Thijs de Gunst, Harm C. den Boer, Marion T.J. van den Bosch, Bryony J. Telford, Rogier M. Vos, Xiaolei Xie, Mingfa Zang, Fang Wang, Yingying Shao, Xiaoyu An, Jingjing Wang, Jie Cai, Ludovic Bourré, Laurens A.H. van Pinxteren, Roel Q.J. Schaapveld, Michel Janicot, and Sanaz Yahyanejad from InteRNA Technologies BV, Utrecht, The Netherlands, and Crown Bioscience Inc., in San Diego, examined the effect of their lipid nanoparticle (LNP) formulated, chemically modified, synthetic miR-193a-3p mimic (INT-1B3) on anti-tumor immunity. “In this study, we examined the effect of our lipid nanoparticle (LNP) formulated, chemically modified, synthetic miR-193a-3p mimic (INT-1B3) on animal survival, tumor microenvironment (TME) and induction of anti-tumor immune responses.” The data presented within the study demonstrates for the first time that miR-193a-3p induces long-term immunity against tumor development via modulation of the tumor microenvironment and induction of immunogenic cell death. Additionally, the data show that systemic administration of INT-1B3 to 4T1 and H22 tumor bearing immunocompetent mice prolonged animal survival by reducing metastasis compared to phosphate buffered saline (PBS) or anti-programmed death (PD) 1 treatment. DOI - https://doi.org/10.18632/oncotarget.28608 Correspondence to - Sanaz Yahyanejad - sanaz.yah@gmail.com Video short - https://www.youtube.com/watch?v=pK_Bs5vMBCQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28608 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, miR-193a-3p, microRNA mimic, T cell mediated immunity, immunogenic cell death About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

san diego reddit netherlands buffalo pbs immunity mir pd bosch tumors vos utrecht boosts boer doi mimic thijs gunst telford lnp microrna tme scopus cell death altmetric pinxteren oncotarget embase ny august

An Era of Promise for Cancer Vaccines

ASCO Daily News

Play Episode Listen Later Jul 11, 2024 19:21

Dr. Pedro Barata and Dr. Lillian Siu discuss recent advances in cancer vaccines and biomarkers, including the potential of the neoantigen and immune modulatory vaccines and the challenges surrounding cancer vaccine development. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host for the ASCO Daily News Podcast today. I'm a GU medical oncologist at the University Hospitals Seidman Cancer Center in Cleveland, Ohio, and an associate professor of medicine at Case Western Reserve University School of Medicine. I'm also an associate editor of the ASCO Educational Book. And today we'll be discussing a timely article that was recently published in the Educational Book titled, “State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.” I'm delighted to welcome one of the article's co-authors and a world-renowned oncologist, Dr. Lillian Siu. She is a senior medical oncologist and director of the Phase 1 Program at the Princess Margaret Cancer Center and a professor of medicine at the University of Toronto. Welcome, Dr. Siu. Dr. Lillian Siu: Thank you, Dr. Barata; it's great to be here. Dr. Pedro Barata: Wonderful. Dr. Siu will discuss new tools for cancer vaccine development, strategies for combating the immunosuppressive and tumor microenvironment. She will also address cancer vaccine guidelines and patient recruitment strategies to optimize patient selection and access to cancer vaccine trials. I should say that Dr. Siu and her co-authors also addressed this topic during an Education Session at the ASCO 2024 Annual Meeting. Finally, our full disclosures are available in the transcript of this episode. So again, Dr. Siu, great to be speaking with you today. I'm looking forward to our discussion. Dr. Lillian Siu: Thank you, Dr. Barata. And before I begin, I want to acknowledge Dr. Jeffrey Weber and Dr. Inge Marie Svane, who both presented during the ASCO session you mentioned. They gave excellent presentations related to the topic of neoantigen vaccines and immune-modulatory vaccines, which we will talk about later. Dr. Pedro Barata: Wonderful. So let's get started. Cancer vaccines are among the most promising frontiers for breakthrough innovations and new strategies in the fight against cancer. The successes in vaccine development during the COVID-19 pandemic, I think, inspired further research in this area. Why do you think it's important that we harness these recent successes and technological advances to really accelerate progress in vaccine development? Dr. Lillian Siu: Absolutely. I think all of us who have lived through COVID really appreciated how important the COVID vaccine development was to all of us. It saved millions of lives. And I think we witnessed a paradigm change in drug development that none of us thought was possible, that we're able to actually bring a concept to a drug from bench to bedside within an extremely short time. That timeline is not something we would ever imagine to have happened, and it did. And I think it gives us hope that perhaps this is not just limited to the COVID vaccine; it's also extrapolatable to other therapeutics – that we can bring promising medicines to our patients in a really expedited timeline, obviously without compromising their safety. We now know that cancer vaccines have entered a new, or maybe I should say, renewed era of promise. And it's holding promise on many fronts, Pedro, if I may. It's very exciting in the area of molecular residual disease. In other words, a setting where the cancer is treated definitively by surgery or radiation, plus adjuvant treatment. And we know some patients will relapse because we know they're at high risk. And now we also have different ways to detect these microscopic risks, such as by ctDNA, circulating tumor DNA, or biomarkers. And we know that having some therapeutic that can eradicate these cancers at such microscopic levels would be very attractive, especially with low toxicity, and I think cancer vaccine is such a candidate. And of course, we can even look further into the future of using such treatment in cancer prevention, especially in those with high risk of developing cancer, for example, those with hereditary syndromes like lynch syndrome. We're not there yet, but I think it holds that promise. So I think, going back to your original question, if we can develop such a therapeutic that is showing promise in a very short period of time, it brings the timeline and the hope to a much shorter timeframe to really deliver to our patients in a very timely manner while safeguarding all the important parts, such as safety and tolerability. Dr. Pedro Barata: Wow, those are such important points. I couldn't agree with you, more. It's really exciting. As I think through this, and as I was reading through your piece, I was thinking it would be great if you could highlight some of the novel approaches to personalized neoantigen vaccine development that are driving progress in this space. Dr. Lillian Siu: Absolutely. And during the session, Dr. Weber spoke about the neoantigen vaccine, and he's a pioneer in this space. So I can only try to iterate some of the points he had delivered during his talk. Neoantigen is a very exciting space for immunologists because we know that tumors express these neoantigens. Many of these are unique antigens that are only expressed in tumors, so-called tumor specific antigens, that we can use as our targets, including vaccines, but not limited to vaccines. And with these altered sequences in DNA in different forms, they could be mutations and splice alterations, etc. We expect that we have modified proteins that are expressed by tumor cells, and these become targets for our drug development of vaccines. And now we can have very specific strategies, very sophisticated algorithms to figure out which neoantigens are more so called immunogenic, more likely to stimulate or activate the immune system, and they can be recognized by T cells. So leveraging this knowledge and technology, we have been able to develop especially mRNA vaccines that are deliverable to our patients through different mechanisms, for example, in lipopeptides, etc., so that we can deliver to the patients in a safe way, such that we can use it to deliver vaccines, such as in the MRD setting that I mentioned earlier, as well as in the advanced disease setting. So Dr. Weber, in his presentation, highlighted one of such vaccines that have been tested in a randomized controlled trial that is KEYNOTE-942, which randomized 157 patients to the mRNA vaccine plus pembrolizumab versus pembrolizumab alone in patients with advanced melanoma. This is a vaccine against 34 mutated neoantigens, and it showed a significant difference in the recurrence free survival with a hazard ratio of 0.56. And if you look at the 18-month relapse free survival rate, it was 78.6% versus 62.2%. Obviously, these are still fairly early data and numbers are still small. I think we would definitely look forward to the randomized phase 3 study of neoantigen vaccine in melanoma and other cancers. Dr. Pedro Barata: No, absolutely. And I agree, it's really exciting. Dr. Weber did a fantastic job going through some of that data. So let me ask you Dr. Siu, as you think about this cancer vaccine field, what are the limitations that you'd highlight when you think about cancer vaccine development? What challenges do you encounter, obstacles do you encounter? Dr. Lillian Siu: There are many, many potential challenges. And to some extent, that's probably why cancer vaccine development has been somewhat slow for the many decades until more recently. We know first of all; the target has to be recognized. So we need immunogenic targets. So I think a lot of the effort has been put into trying to understand which antigens expressed by cancer cells are immunogenic, able to activate the immune system. They're obviously assay based methods. You're going to try and see if you can ex vivo stimulate immune cells on dishes and models, etc. But we need to also develop in silico computerized algorithms, and now with AI, I think that makes it even more tangible and exciting that we can actually understand through a large number of neoantigens or other antigens, whether we can choose the ones that are most likely going to actually stimulate T cells to be activated. And I think that is one area that there is a lot of interest in development, how to really develop ways to select out the most attractive antigens. I would also want to highlight that the platforms, which is how we deliver the vaccine, can also pose significant challenges. For example, vaccines can be delivered using peptide-based formulation, cell-based formulation, nucleic acids and viral vectors. For some of these formulations, for example, the peptides very often are restricted to HLA. They can be rapidly degraded in the body, such that they become not really visible to the T cells anymore. Some of the formulations can be very complex. For example, the cell-base; it may need to have cells isolated from patients, cultured, stored and transported to the site of delivery, which can be very complex. For some of the nucleic acid vaccines, they can have very low transfection efficiency. It could be at risk for also having, for example, DNA vaccines integrated into the host genome. And then lastly, there's also the immune suppressive environment in the TME, such that it does not really have the effect when you give it repeatedly. It becomes attenuated and no longer effective. So these are some of the challenges associated with cancer vaccines. Dr. Pedro Barata: Thank you for that summary. I think it's really important for folks out there, including researchers getting into this field, to be aware of potential obstacles they might encounter. So let me ask you the opposite question as we see more compelling preclinical and clinical data emerging in this field of vaccine development, what is really exciting you the most about the newest technologies that are shaping the future of cancer vaccines, in your opinion? Dr. Lillian Siu: I think one I want to highlight is the immune-modulatory vaccine that Dr. Svane, Dr. Inge Marie Svane had presented during the presentation at ASCO. This is a completely different strategy from the neoantigen vaccine. It targets antigens in the tumor microenvironment. And we know that in the tumor microenvironment, we have tumor cells, we have immune cells, and there are many types of cell types, including, for example, macrophages, cancer associated fibroblasts, regulatory T cells, etc. And using these particular cell types, we know that we can really develop vaccines that can stimulate the body's immune system to attenuate, to downgrade some of the negative factors in the tumor microenvironment. And this is what Dr. Svane and her group is trying to do. For example, they have an IDO vaccine that is able to actually target these antigens in the tumor microenvironment, and by that, not just suppressing the negative forces, so to speak, but also activate T cells to help attack cancer cells. I think that's a very interesting area. Very early promise has been seen already in non-small cell lung cancer in early phase trials using the immune-modulatory vaccine. But going back to your question, what kind of advances; I mentioned earlier about having novel ways to select our antigens that are most immunogenic. There are many algorithms that are being developed, and I think we can try and leverage that kind of knowledge from artificial intelligence, machine learning. So I think that's definitely very exciting. There are also new vaccine platforms coming out. For example, there's recent data using modification of peptides, so called amphiphile vaccines, that already show very early promise in colorectal cancer, microsatellite status, colorectal cancer, as well as in pancreatic cancer in the molecular residual disease setting, where these long peptide vaccines targeting KRAS mutants together with adjuvant oligonucleotide DNA, combined together, can actually be given to patients and reduce the chance of cancer relapse in patients with resected colorectal cancer, as well as pancreatic cancer, with endpoints such as ctDNA or biomarker being downregulated. I think that's a very exciting example. Another very exciting example is cell-based vaccines that are being developed in Europe by the NKI Netherlands Cancer Institute Group, where they are looking at plasmacytoid dendritic cells that are loaded with peptides from different tumor associated antigens and then given to patients, which, again, in non-small cell lung cancer, together with pembrolizumab, has yielded very high response rate. And we will almost certainly see more trials coming out using that particular platform with the dendritic cells. So that's just some of the examples of exciting things that are happening in the vaccine field. Dr. Pedro Barata: Thank you. I'm wondering if you can share with our listeners about what really are the existing guidelines for using these new tools for discovery, methods of treatment, and perhaps optimizing patient selection to access trials. Dr. Lillian Siu: To be honest, the latest guideline that was published from the FDA that I can find is almost 13 years ago in 2011. So I think it is time for a new guidance, or at least a draft guidance, to give some additional support and guidance in terms of what to do with these new treatments from the FDA and perhaps other regulatory agencies as well. I think we're now entering a very exciting time that cancer vaccines are no longer an ineffective therapeutic. It is now showing evidence of efficacy, not just in the advanced setting, but also in the molecular residual disease setting. There're so many questions to be answered, like how to develop these trials in early disease; what's the end point? Can we incorporate them into the neoadjuvant setting, and if so, how do we give these drugs before surgery, and do we give them maintenance after surgery? I think guidance from the regulatory authorities would be extremely helpful and informative to guide academic groups as well as the pharmaceutical sector to develop these agents in the right way. Dr. Pedro Barata: Dr. Siu, this is a fantastic summary, and we certainly are on the cusp of a new dawn of discovery and development in cancer vaccines, and super interesting to hear from you talking about it. Before letting you go, do you have any final thoughts that you'd like to share with the listeners, with all of us about this topic? Dr. Lillian Siu: I think as a drug developer like you are, I'm extremely excited because we now have yet another way to leverage the host immunity as a cancer therapeutic, and it is going to be opening a new door to combination therapy because we can imagine combining these treatments with other immunotherapeutics such as bispecific molecules such as CAR Ts and even vaccine plus vaccine combination is feasible. That came up actually during the session as a question from the audience. Can we combine neoantigen vaccines and immune-modulatory vaccines together? And both of our speakers who presented felt that it was possible. Obviously, we have to understand the sequence question and the endpoints question, but the fact that it opens a new door to combinatorial therapy, not just with immunotherapeutics, but perhaps with other therapeutics as well, antibody drug conjugates, etc., really, I think, is very exciting for this field to become further explored. I mentioned earlier in the podcast that the whole area of cancer prevention is something that we have not been tapping into for the last decade with vaccines because it has not been very effective. Viral vaccines, of course, HPV and other vaccines targeting viruses, but targeting cancer cells is not something we have been successful using vaccines to prevent cancer from developing. I think we would be very interested to see if this will become a reality in the next decade. I think we would start off with patients with high risk of developing cancers such as, as I mentioned earlier, those with lynch syndrome, those harboring BRCA alterations, for example. Can we use these vaccines to actually prevent the cancers from developing in such high-risk individuals? I think the field is definitely open to that consideration. Dr. Pedro Barata: Definitely. And I'd like to thank you, Dr. Siu, for sharing these great insights with us today on the ASCO Daily News Podcast. Dr. Lillian Siu: Thank you so much for your time. Dr. Pedro Barata: And thank you to all the listeners for your time today. You'll find a link to the article discussed today in the transcript of this episode, and I encourage you to check out the 2024 ASCO Educational Book. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So again, thank you so much for your time and see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Pedro Barata @PBarataMD Dr. Lillian Siu @lillian_siu Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Pedro Barata: Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Dendreon Speakers' Bureau (Inst): Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Blueearth, AVEO, Pfizer, Merck Dr. Lillian Siu: Leadership (Immediate family member): Treadwell Therapeutics Stock and Other Ownership Interests (Immediate family member): Agios Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen

I'm DJing My Sister's Funeral that Weekend with Aparna Nancherla

sister funeral djing aparna aparna nancherla tme

Play Episode Listen Later Jun 25, 2024 60:08

Oh haaaay! On this week's gorgina episode of TME, we have the one and only Aparna Nancherla! And she brought the goods. Aparna is telling me everything that she loves about BRITISH MURDER MYSTERY AUDIOBOOKS, the NORMAL GOSSIP PODCAST, and - and this might be the most niche pick yet! - BOUGIE INDIE COFFEE SHOPS THAT ALL LOOK THE SAME. She's a damn treat and a damn delight. Listen up and enjoy bbs! If you like this show, don't forget to rate, review, and subscribe! Be sure to follow the show on Instagram: @tellliameverything And follow me (your host!) across all platforms: @liamgareau

A Great Moment for Me, and Therefore the World with Vincent Martella

dark knight superbad great moments tme vincent martella

Play Episode Listen Later Jun 11, 2024 73:06

We're back atcha with a brand new episode, babes! On this week's glorious ep of TME, the absolute stunner, Vincent Martella is this week's guest. On today's show, Vincent is telling me everything about why he's pissed over THE DARK KNIGHT getting an Oscar snub, why he loves SUPERBAD, and RAY ALLEN'S ICONIC 3-POINTER SHOT FOR THE MIAMI HEAT! If you like this show, don't forget to rate, review, and subscribe! Be sure to follow the show on Instagram: @tellliameverything And follow me (your host!) across all platforms: @liamgareau

043 Motherhood on the Move: Olivia Shockley

motherhood south dakota pnw shockley tme

Play Episode Listen Later May 28, 2024 53:32

Making a move from the PNW to rural South Dakota is no small feat. Olivia's story of motherhood and moving out here to plant roots (sight unseen!) is one you'll find encouraging and incredible. Her experience is unique and endearing and I'm excited to feature her on this episode of TME.Learn more about Olivia & her work Looking to save money on quality, bulk foods? Shop Azure StandardWatch on YouTubeVisit The Motherhood Experience WebsiteFollow us on InstagramFind us on FacebookLooking to save money on quality, bulk foods? Shop Azure StandardWatch on YouTubeVisit The Motherhood Experience WebsiteFollow us on InstagramFind us on Facebook

Immunotherapy drives mesenchymal shift in GBM

Neuro-Oncology: The Podcast

Play Episode Listen Later May 17, 2024 24:18

Dr. Maya Graham interviews Drs. Josephine Hendriksen and Joachim Weischenfeldt about their recent manuscript, "Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients," published online in Neuro-Oncology in May 2024.

shift drives drs immunotherapy tme mesenchymal neuro oncology

Always on the Brink of Chaos with Eliot Glazer

chaos buckle worse brink tme eliot glazer adele dazeem

Play Episode Listen Later Apr 30, 2024 65:46

Hey, HEY, HEY!!! On this week's gorgina episode of TME, we are joined by the absolute stunner, Eliot Glazer (You're Making it Worse). And Eliot's pop culture picks are some all-timers. First up, we got PATTI LABELLE'S CUPCAKE FIASCO ON THE TYRA BANKS SHOW, THE VIEW, and a moment that truly shaped us all - ADELE DAZEEM. Buckle up, my babes, and enjoy! If you like this show, don't forget to rate, review, and subscribe! Be sure to follow the show on Instagram: @tellliameverything And follow me (your host!) across all platforms: @liamgareau

Answering Your Cardinals Questions

Doug Franz Unplugged

Play Episode Listen Later Apr 9, 2024 110:30

00:00 Four-Minute Offense 7:42 Pray for Them! 13:52 Quick D-Backs 15:25 I Kissed Hilary Johnson 19:43 Doug's Big One = NAIA vs Transgender Women 30:20 The NCAA National Championship 1:06:35 Get Off Diana 1:15:47 Town Hall Tuesday (Lots of Cards) 1:34:20 TME with Tons of Coyotes News 1:42:44 Vs Vegas

pray answering cards cardinals tme

Ep. 564 – Dedication to a Place – 130 Years of Waterfowl and Wildlife Science in the Illinois River Valley

Ducks Unlimited Podcast

Play Episode Listen Later Mar 26, 2024 76:36

The Forbes Biological Station in Havanna, Illinois, is North American's oldest inland wildlife research station. Over its 130-year history, it has become one of our greatest sources of scientific information for waterfowl ecology and management. In this episode, Dr. Mike Brasher visits with current staff of the Station – Dr. Auriel Fournier, Josh Osborne, and Therin Bradshaw – to celebrate the 130-year anniversary; pay tribute to its pioneering leaders of the name Forbes, Bellrose, Havera, and others; and reflect on the Station's contributions on topics including wood ducks, migration ecology, aerial surveys, lead poisoning, sanctuary management, wetland management, foraging ecology, and new research on duck foods and the effect of hunting disturbance on bird movements. And hear also what it's like to flip through the pages of an 84-year-old field notebook of Dr. Frank Bellrose.www.ducks.org/DUPodcast

I Like Being Invited Places with Roz Hernandez

Play Episode Listen Later Mar 19, 2024 60:04

We're back, baby! And this time around we're joined by the gorgina Roz Hernandez (“Ghosted!”). This week on TME, Roz is telling me everything about her pop culture picks. And she's got some good ones! We're going over her Hulu show LIVING FOR THE DEAD, as well as HACKS, and the Queen of Drag, RUPAUL. Strap in and get ready for some laughs and some real talk! If you like this show, don't forget to rate, review, and subscribe! Be sure to follow the show on Instagram: @tellliameverything And follow me (your host!) across all platforms: @liamgareau

places hulu hacks strap drag rupaul tme roz hernandez

Earnings Call Analysis: Tencent Music Entertainment - TME

PSFK's PurpleList

Play Episode Listen Later Mar 19, 2024 3:01

Tencent Music Entertainment has disseminated their earnings report, in which CEO Ross Liang shared, "Our total monthly subscribers have reached 107 million already, which is a new milestone to us. We are optimistic about the industry's future and believe that our users, central operations, and expertise will continue to drive the business forward. We are committed to being a popular all-in-one music and audio platform." This statement symbolizes the company's encouraging trajectory in the highly competitive music and entertainment sector. The progress of Tencent Music Entertainment is largely due to its unwavering commitment to providing exceptional content and enhancing the platform experience for its users. The company has been forging strategic alliances with leading domestic and international record labels and focusing on the production of original content, resulting in a comprehensive library of copyrighted music that addresses diverse audience preferences. Crucially, Tencent Music Entertainment has effectively incorporated innovative technologies into its operations, harnessing the latest developments in large language models to optimally recommend music and enable user interaction through singing and socializing. As CEO Ross Liang put it, "We have been closely monitoring the latest development of large language models and integrated it into music recommendations and creations as well as singing and socializing." The company's Q4 2023 report highlights growth in overall revenues, with particular strength in online music revenues and music subscriptions. The increasing paying user base, now over 100 million monthly subscribers, implies a growing readiness among consumers to pay for high-quality music content and shows promise for the growth of music services. Furthermore, Tencent Music Entertainment's strategic adjustments to align with evolving consumer trends, combined with its rigorous product and service execution, have been vital for its user growth and retention. Looking forward, Tencent Music Entertainment plans to navigate this growth path by dedicating more resources towards the production of high-quality and original content. The company is investigating ways to diversify its revenue streams, including stepping into the advertising and artist merchandise sectors. However, it's crucial to note that any positive industry trends and the company's dedication to capitalizing on emerging opportunities are based on the company's internal forecasts and assessments, warranting the need for continuous evaluation. Furthermore, the firm's commitment to social responsibility, evidenced in its endeavors to boost cultural and economic development in ethnic minority areas, demonstrates a balanced growth approach. In summary, the Q4 2023 performance of Tencent Music Entertainment, characterized by strategic content development, user engagement initiatives, and future investment plans, indicates a potentially promising trajectory for the company in the evolving landscape of the music industry. However, its future performance will largely depend on maneuvering through any industry challenges and ensuring the successful execution of its outlined strategies. TME Company info: https://finance.yahoo.com/quote/TME/profile For more PSFK research : www.psfk.com This email has been published and shared for the purpose of business research and is not intended as investment advice.

tencent crucially earnings call tme psfk call analysis tencent music entertainment

Is This Show H*rny Enough with Eric Williams

The Mindful Experiment Podcast

Play Episode Listen Later Mar 5, 2024 65:09

Babies, here comes ANOTHER ONE. On this week's episode of “Tell Me Everything,” we have the glorious, Eric Williams (“That's a Gay Ass Podcast”). And god bless ‘em, because he's really pulling out all stops. Eric's gorgeous pop culture pulls are PIERCE BROSNAN'S CHEST HAIR IN MRS. DOUBTFIRE, THE FAMILY STONE, and MANDY MOORE'S POP CAREER. Mama, we laugh, we love, we lament. In other words - another classic episode of TME - enjoy! If you like this show, don't forget to rate, review, and subscribe! Be sure to follow the show on Instagram: @tellliameverything And follow me (your host!) across all platforms: @liamgareau

babies mama another one doubtfire family stone eric williams tell me everything tme gay ass podcast

EP#496 - Release the Patterns That Don't Serve You with Guest: Dr. Charryse Johnson

Play Episode Listen Later Feb 29, 2024 30:53

In this episode of TME#496, guest Dr. Charryse Johnson shares insights into releasing patterns that don't serve us, stemming from her personal journey through trauma and healing. Growing up as the youngest of eight in a household filled with diverse reactions to challenges, Johnson's early exposure to trauma and observation of varying coping mechanisms sparked her interest in human development and psychology. She pursued these fields with the aim of understanding the intricacies of healing and helping others navigate their own paths towards wellness. Johnson emphasizes that healing is a continuous process, likening it to the care and rehabilitation required after a physical injury. She challenges the notion that one can ever be "fully healed," proposing instead that healing evolves over time, requiring ongoing attention and adjustment. The conversation delves into the definition of trauma, broadening it beyond extreme events to include any experience that exceeds an individual's capacity to cope at the time. Johnson's approach to healing focuses on self-awareness, acknowledging pain without dwelling on it, and actively choosing pathways towards personal growth and resilience. She underscores the importance of mindful check-ins and diaphragmatic breathing as practical tools for fostering a healing mindset throughout daily life.Who is Dr. Charryse Johnson?Dr.Charryse Johnson, LCMHC, NCC is a veteran psychotherapist and mindfulness practitioner whose work focuses on the intersection of trauma, somatic integration, spirituality, and social justice. She is the founder of Jade Integrative Counseling and Wellness, an integrative therapy practice where personal values, the search for meaning, and the power of choice are the central focus. Charryse holds a B.A. in human development and family studies; an M.A. in professional counseling and a Ph.D. in Counseling Psychology with a concentration in crisis and trauma. How to Connect with Dr. Charryse?Website: www.drcharryse.com SocialsInstagram: https://www.instagram.com/dr.charryse_j/ Facebook: https://www.facebook.com/jaedintegrativeLinkedIn: https://www.linkedin.com/in/drch Hosted on Acast. See acast.com/privacy for more information.

wellness serve acast patterns counseling psychology ncc lcmhc tme

030 The Melody of Motherhood: Bridgette Bitzegaio

Play Episode Play 30 sec Highlight Listen Later Feb 27, 2024 42:04

Adapt Music's WebsiteBridgette is a wife, mom, teacher, and musical-joy-spreader. I've known her since I started working with her husband back in 2008! I was thrilled when she agreed to be a guest on TME podcast because with three busy kids, a full-time job, and running her nonprofit, I knew she'd have a story or two to share. Her bright, bubbly spirit is only one of the many reasons I adore her, and I know you'll enjoy this conversation with her.Watch on YouTubeVisit The Motherhood Experience WebsiteFollow us on InstagramFind us on Facebook

motherhood tme

029 When Faith Yields Fruit: The Motherhood Experience Conversation with Holli Bromenshenkel

conversations fruit motherhood yields tme

Play Episode Play 23 sec Highlight Listen Later Feb 20, 2024 46:10

Holli is a new friend! I had never spoken with her before our conversation for the podcast. When I heard her story of how the little steps of faith produced exceptional fruit and how the puzzle pieces of her motherhood journey started revealing the bigger picture, I was blown away! No doubt you will be, too. I'm glad to have met Holli's acquaintance, and I'm glad she allowed me to share her story with the TME listeners!Watch on YouTubeVisit The Motherhood Experience WebsiteFollow us on InstagramFind us on Facebook

PROX1/α-SMA Correlated With Colorectal Cancer Progression, Poor Outcomes and Therapeutic Resistance

Aging-US

Play Episode Listen Later Feb 7, 2024 4:03

BUFFALO, NY- February 7, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 2, entitled, “PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance.” The tumor microenvironment (TME) plays a vital role in tumor progression through intricate molecular interactions. Cancer-associated fibroblasts (CAFs), notably those expressing alpha-smooth muscle actin (α-SMA) or myofibroblasts, are instrumental in this context and correlate with unfavorable outcomes in colorectal cancer (CRC). While several transcription factors influence TME, the exact regulator causing CAF dysregulation in CRC remains elusive. Prospero Homeobox 1 (PROX1) stands out, as its inhibition reduces α-SMA-rich CAF activity. However, the therapeutic role of PROX1 is debated due to inconsistent study findings. In this new study, researchers Shiue-Wei Lai, Yi-Chiao Cheng, Kee-Thai Kiu, Min-Hsuan Yen, Ying-Wei Chen, Vijesh Kumar Yadav, Chi-Tai Yeh, Kuang-Tai Kuo, and Tung-Cheng Chang from Taipei's National Defense Medical Center, Taipei Medical University, Taipei Medical University Shuang-Ho Hospital, and National Taitung University used the ULCAN portal and noted an elevated PROX1 level in advanced colon adenocarcinoma, linking to a poor prognosis. Their assays determined the impact of PROX1 overexpression on CRC cell properties, while co-culture experiments spotlighted the PROX1-CAF relationship. Molecular expressions were validated by qRT-PCR and Western blots, with in vivo studies further solidifying the observations. “Our study emphasized the connection between PROX1 and α-SMA in CAFs.” Elevated PROX1 in CRC samples correlated with increased α-SMA in tumors. PROX1 modulation influenced the behavior of specific CRC cells, with its overexpression fostering invasiveness. Kaplan-Meier evaluations demonstrated a link between PROX1 or α-SMA and survival outcomes. Consequently, PROX1, alone or with α-SMA, emerges as a CRC prognostic marker. Co-culture and animal experiments further highlighted this relationship. PROX1 appears crucial in modulating CRC behavior and therapeutic resistance within the TME by influencing CAFs, signifying the combined PROX1/α-SMA gene as a potential CRC prognostic marker. The concept of developing inhibitors targeting this gene set emerges as a prospective therapeutic strategy. However, this study is bound by limitations, including potential challenges in clinical translation, a focused exploration on PROX1/α-SMA potentially overlooking other significant molecular contributors, and the preliminary nature of the inhibitor development proposition. “As we advance in this field, the development and clinical validation of small-molecule inhibitors targeting PROX1/α-SMA become imperative, paving the way to refine and optimize CRC therapeutic interventions.” DOI - https://doi.org/10.18632/aging.205447 Corresponding author - Tung-Cheng Chang - 09432@s.tmu.edu.tw About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Visit our website at https://www.Aging-US.com. MEDIA@IMPACTJOURNALS.COM

covid-19 western cancer poor web resistance buffalo outcomes progression therapeutic molecular taipei sma doi colorectal cancer crc correlated tme kaplan meier qrt pcr prox1

Pelvic Exenteration Surgery Series Episode 4: Reconstruction and Recovery

Play Episode Listen Later Jan 25, 2024 34:52

Join Professor Michael Solomon, Dr Kilian Brown and Dr Jacob Waller from Royal Prince Alfred Hospital in Sydney, Australia, for this special four part series on pelvic exenteration surgery for locally advanced and recurrent rectal cancer. Learn about these ultra-radical procedures which go beyond the traditional TME planes that we learn during surgical training, and into all compartments of the pelvis. Episode 4 outlines the complex perineal and soft tissue, urological, bone and vascular reconstructions that may be required as part of these multi-visceral resections, as well as how to approach challenging postoperative complications. Each episode in this series features a different international guest surgeon. In episode 4, the RPA team are joined by A/Prof Gabrielle van Ramshorst from the Ghent University Hospital, Belgium. Technical descriptions: Ho K, Warrier S, Solomon MJ, Lee K. A prepelvic tunnel for the rectus abdominis myocutaneous flap in perineal reconstruction. J Plast Reconstr Aesthet Surg. 2006;59(12):1415-9. doi: 10.1016/j.bjps.2006.01.050. Epub 2006 Jun 22. PMID: 17113532. https://pubmed.ncbi.nlm.nih.gov/17113532/ Jacombs AS, Rome P, Harrison JD, Solomon MJ. Assessment of the selection process for myocutaneous flap repair and surgical complications in pelvic exenteration surgery. Br J Surg. 2013 Mar;100(4):561-7. doi: 10.1002/bjs.9002. Epub 2012 Nov 27. PMID: 23188415. https://pubmed.ncbi.nlm.nih.gov/23188415/ References: Witte DYS, van Ramshorst GH, Lapid O, Bouman MB, Tuynman JB. Flap Reconstruction of Perineal Defects after Pelvic Exenteration: A Systematic Description of Four Choices of Surgical Reconstruction Methods. Plast Reconstr Surg. 2021 Jun 1;147(6):1420-1435. doi: 10.1097/PRS.0000000000007976. PMID: 33973948. https://pubmed.ncbi.nlm.nih.gov/33973948/ van Ramshorst GH, Young JM, Solomon MJ. Complications and Impact on Quality of Life of Vertical Rectus Abdominis Myocutaneous Flaps for Reconstruction in Pelvic Exenteration Surgery. Dis Colon Rectum. 2020 Sep;63(9):1225-1233. doi: 10.1097/DCR.0000000000001632. PMID: 33216493. https://pubmed.ncbi.nlm.nih.gov/33216493/ Sutton PA, Brown KGM, Ebrahimi N, Solomon MJ, Austin KKS, Lee PJ. Long-term surgical complications following pelvic exenteration: Operative management of the empty pelvis syndrome. Colorectal Dis. 2022 Dec;24(12):1491-1497. doi: 10.1111/codi.16238. Epub 2022 Jul 19. PMID: 35766998. https://pubmed.ncbi.nlm.nih.gov/35766998/ Johnson YL, West MA, Gould LE, Drami I, Behrenbruch C, Burns EM, Mirnezami AH, Jenkins JT. Empty pelvis syndrome: a systematic review of reconstruction techniques and their associated complications. Colorectal Dis. 2022 Jan;24(1):16-26. doi: 10.1111/codi.15956. Epub 2021 Oct 25. PMID: 34653292. https://pubmed.ncbi.nlm.nih.gov/34653292/ Persson P, Chong P, Steele CW, Quinn M. Prevention and management of complications in pelvic exenteration. Eur J Surg Oncol. 2022 Nov;48(11):2277-2283. doi: 10.1016/j.ejso.2021.12.470. Epub 2022 Jan 1. PMID: 35101315. https://pubmed.ncbi.nlm.nih.gov/35101315/ Lee P, Tan WJ, Brown KGM, Solomon MJ. Addressing the empty pelvic syndrome following total pelvic exenteration: does mesh reconstruction help? Colorectal Dis. 2019 Mar;21(3):365-369. doi: 10.1111/codi.14523. Epub 2019 Jan 16. PMID: 30548166. https://pubmed.ncbi.nlm.nih.gov/30548166/ Video Link: https://www.youtube.com/watch?v=GBC-ZD0B7UM ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9*** Please visit https://app.behindtheknife.org/home to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here https://app.behindtheknife.org/listen

australia recovery impact addressing belgium empty surgery technical reconstruction complications pelvic epub prs rpa operative pmid tme dcr royal prince alfred hospital surgery series

Bestie Time: The hottest lingo, Reed as Beyoncé, and all the gossip on Tinman Elite

Play Episode Listen Later Jan 23, 2024 46:48

Katie Camarena and Savannah Shaw sit down for some quality 'Bestie Time' to discuss their first few months with Tinman Elite, their latest jargon of choice, and TME's roster as pop stars.

beyonce gossip hottest besties lingo tin man tme tinman elite

Pelvic Exenteration Surgery Series Episode 3: Posterior and Lateral Compartment Tumours

Play Episode Listen Later Jan 22, 2024 37:35

Join Professor Michael Solomon, Dr Kilian Brown and Dr Jacob Waller from Royal Prince Alfred Hospital in Sydney, Australia, for this special four part series on pelvic exenteration surgery for locally advanced and recurrent rectal cancer. Learn about these ultra-radical procedures which go beyond the traditional TME planes that we learn during surgical training, and into all compartments of the pelvis. Episode 3 outlines the radical technical approaches to posterior and laterally invasive tumours, including en bloc iliac vascular resection and reconstruction, as well as radical sacrectomy techniques. Each episode in this series features a different international guest surgeon. In episode 3, the RPA team are joined by Dr Oliver Peacock from the University of Texas MD Anderson Cancer Centre, USA. Technical descriptions and videos: Shaikh I, Holloway I, Aston W, Littler S, Burling D, Antoniou A, Jenkins JT; Complex Cancer Clinic St Mark's Hospital London. High subcortical sacrectomy: a novel approach to facilitate complete resection of locally advanced and recurrent rectal cancer with high (S1-S2) sacral extension. Colorectal Dis. 2016 Apr;18(4):386-92. doi: 10.1111/codi.13226. PMID: 26638828. https://pubmed.ncbi.nlm.nih.gov/26638828/ Brown KGM, Solomon MJ, Austin KKS, Lee PJ, Stalley P. Posterior high sacral segmental disconnection prior to anterior en bloc exenteration for recurrent rectal cancer. Tech Coloproctol. 2016 Jun;20(6):401-404. doi: 10.1007/s10151-016-1456-0. Epub 2016 Mar 21. PMID: 27000857. https://pubmed.ncbi.nlm.nih.gov/27000857/ Sutton PA, Solomon M, Sasidharan P, Lee P, Austin K. Abdominolithotomy sacrectomy for the management of locally recurrent rectal cancer: video vignette. Br J Surg. 2021 Aug 19;108(8):e257. doi: 10.1093/bjs/znab105. PMID: 34089593. https://pubmed.ncbi.nlm.nih.gov/34089593/ Drami I, Fletcher JA, Corr A, West MA, Aston W, Hellawell G, Burns EM, Jenkins JT. Total pelvic exenteration with 'high and wide' sacrectomy for recurrent rectal cancer: A video vignette. Colorectal Dis. 2022 Dec;24(12):1625-1626. doi: 10.1111/codi.16230. Epub 2022 Jul 18. PMID: 35730692. https://pubmed.ncbi.nlm.nih.gov/35730692/ References: Rajendran S, Brown KGM, Solomon MJ. Oncovascular surgery for advanced pelvic malignancy. Br J Surg. 2023 Jan 10;110(2):144-149. doi: 10.1093/bjs/znac414. PMID: 36427187. https://pubmed.ncbi.nlm.nih.gov/36427187/ Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement. Dis Colon Rectum. 2009 Jul;52(7):1223-33. doi: 10.1007/DCR.0b013e3181a73f48. PMID: 19571697. https://pubmed.ncbi.nlm.nih.gov/19571697/ Rogers AC, Jenkins JT, Rasheed S, Malietzis G, Burns EM, Kontovounisios C, Tekkis PP. Towards Standardisation of Technique for En Bloc Sacrectomy for Locally Advanced and Recurrent Rectal Cancer. J Clin Med. 2021 Oct 25;10(21):4921. doi: 10.3390/jcm10214921. PMID: 34768442; PMCID: PMC8584798. https://pubmed.ncbi.nlm.nih.gov/34768442/ van Kessel CS, Waller J, Steffens D, Lee PJ, Austin KKS, Stalley PD, Solomon MJ. Improving Surgical Outcomes in Pelvic Exenteration Surgery: Comparison of Prone Sacrectomy with Anterior Cortical Sacrectomy Techniques. Ann Surg. 2023 Jul 24. doi: 10.1097/SLA.0000000000006040. Epub ahead of print. PMID: 37485983. https://pubmed.ncbi.nlm.nih.gov/37485983/ ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9*** Please visit https://app.behindtheknife.org/home to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here https://app.behindtheknife.org/listen

united states university australia surgery technical technique pelvic epub lateral rpa sla pmid posterior compartment tumours tme dcr royal prince alfred hospital s1 s2 surgery series ann surg

Therapeutically Harnessing Cancer Stem Cell-derived Exosomes

Oncotarget

Play Episode Listen Later Jan 3, 2024 2:55

BUFFALO, NY- January 3, 2024 – A new #editorial paper was #published in Oncotarget's Volume 14 on December 20, 2023, entitled, “Therapeutically harnessing cancer stem cell-derived exosomes.” In this editorial, researcher Yong Teng from Emory University discusses cancer stem cell-derived exosomes. Cancer stem cells (CSCs), a small population of cancer cells capable of self-renewal, are thought to serve as a central hub for tumor initiation, growth, metastasis, and recurrence. The potential for using CSCs in the diagnosis and treatment of cancer is gaining recognition. Exosomes are formed when multivesicular endosomes or multivesicular bodies fuse with the outer membrane of the cell, releasing various components such as DNA, RNA, lipids, metabolites, and cytosolic and cell surface proteins. “Over the past decade, our understanding of the characteristics and function of cancer-associated exosomes has expanded rapidly.” As the major messengers, exosomes present in the tumor microenvironment (TME) play a critical role in maintaining the delicate balance between CSCs and non-CSCs. Given the importance of CSCs, it is reasonable to believe that CSC-derived exosomes (CSC-Exos) are essential for communication between CSCs and other cells in the TME. Accumulating evidence has demonstrated that CSC-Exos contribute significantly to almost all fundamental aspects of cancer, including maintaining a continuous cycle of self-renewal within the TME, exerting control over neighboring or distant cells, enabling cancer cells to evade immune surveillance, and promoting immune tolerance. “A deeper understanding of the characteristics and functions of CSC-Exos has the potential to lay the foundation for the development of novel clinical tools for diagnosis and prognosis, as well as therapies aimed at preventing tumor progression and recurrence.” DOI - https://doi.org/10.18632/oncotarget.28542 Correspondence to - Yong Teng - yong.teng@emory.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28542 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cancer stem cells, exosomes, the tumor microenvironment, therapeutic target, anticancer strategy About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

dna cancer soundcloud reddit buffalo harnessing emory university stem cells rna doi cscs derived csc accumulating exosomes tme therapeutically altmetric oncotarget

Savannah Shaw, Inside the Women's Wolfpack, Adjusting Expectations, Why TME?

women spotify expectations mt shaw adjusting raleigh rushmore nc state wolfpack tme pillar performance

Play Episode Listen Later Dec 27, 2023 79:42

Meet Savannah Shaw, one of TME's newest female athletes! Tune in to get the inside scoop on the NC State ladies' success, how Savannah has adjusted her expectations to maximize her success, why she chose TME, her favorite spots Raleigh, and who's on her Mt. Rushmore.Tin Talk is brought to you by Pillar Performance. To maximize your performance, recovery, and sleep habits check them out at https://thefeed.com/collections/pillar-performance and use code 'TINTALK' for 15% off.As always, let us know how we did in the comments, shoot us a question, or just tell us how you're doing.Follow Savannah: https://www.instagram.com/alldayrunning/?hl=enFollow Sam: https://www.instagram.com/par_sam_sons/Follow Joey: https://www.instagram.com/joeyberriatua/Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/tin-talk/id1655195155Listen on Spotify: https://open.spotify.com/show/4g6N0gTk4bpEJHxFzu0Mrr

Welcoming Anthony Camerieri, favorite gear, and the highs and lows of running

spotify running ncaa gear highs and lows dmr tme pillar performance

Play Episode Listen Later Dec 20, 2023 57:58

Meet Anthony Camerieri, one of TME's newest athletes. Learn about Anthony's background, DMR expertise, not making NCAAs and the rest of his process to becoming the professional athlete that he is today.Tin Talk is brought to you by Pillar Performance. To maximize your performance, recovery, and sleep habits check them out at https://thefeed.com/collections/pillar-performance and use code 'TINTALK' for 15% off. As always, let us know how we did in the comments, shoot us a question, or just tell us how you're doing.Follow Anthony: https://www.instagram.com/anthony_camerieri/Follow Sam: https://www.instagram.com/par_sam_sons/Follow Joey: https://www.instagram.com/joeyberriatua/Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/tin-talk/id1655195155Listen on Spotify: https://open.spotify.com/show/4g6N0gTk4bpEJHxFzu0Mrr

The Exponential Improvement of Katie Camarena

spotify exponential camarena tme more importantly pillar performance

Play Episode Listen Later Dec 13, 2023 80:25

Have you even wondered which TME member would be what sea creature? Well... now you don't have to. Join the boys as they catch up, analyze the athletics stock market, and MORE IMPORTANTLY get to know one of TME's newest members: Katie Camarena!!!(Also, sorry for the weird audio... We had some mic issues today!)Tin Talk is brought to you by Pillar Performance. To maximize your performance, recovery, and sleep habits check them out at https://thefeed.com/collections/pillar-performance and use code 'TINTALK' for 15% off.As always, let us know how we did in the comments, shoot us a question, or just tell us how you're doing.Follow Katie: https://www.instagram.com/katieecamarena/?hl=enFollow Sam: https://www.instagram.com/par_sam_sons/Follow Joey: https://www.instagram.com/joeyberriatua/Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/tin-talk/id1655195155Listen on Spotify: https://open.spotify.com/show/4g6N0gTk4bpEJHxFzu0Mrr

Marc Hunter's Impressive Career, Dirty Bath Water, and Elevating TME | Tin Talk S2E6

Play Episode Listen Later Dec 6, 2023 88:19

After Sam and Joey kick off the Pod, Marc Hunter sits down for a deep dive into his athletic career, the early days of the Boulder running scene, and what it's like trying to recruit the best athletes that TME can get.Talking Points: Stock up, Stock Down, TME as Collegiate Programs, Marc Hunter, Athletics West, Shooting for the 1980 Olympics, Dirty Bath Water, Bolder Boulder, Recruiting for TME, Marc's Mt Rushmore.Tin Talk is brought to you by Pillar Performance. To maximize your performance, recovery, and sleep habits check them out at https://thefeed.com/collections/pillar-performance and use code 'TINTALK' for 15% off.As always, let us know how we did in the comments, shoot us a question, or just tell us how you're doing.Follow Sam: https://www.instagram.com/par_sam_sons/Follow Joey: https://www.instagram.com/joeyberriatua/

olympic games career shooting recruiting boulder colorado mount rushmore elevating impressive bathwater stock down tme pillar performance bolder boulder

STOCK UP, STOCK DOWN

thanksgiving talking points flagstaff blacksburg usatf stock up stock down new recruits tme pillar performance

Play Episode Listen Later Nov 22, 2023 75:56

This week Joey and Sam get into the best stock purchases they could make in track and field, who would be what dish at Thanksgiving, and a whole number of other topics seen below. Check us out, fam.Talking Points: How the hell are we doin?, Quick training update, New Segment: Stock up, Stock Down (Oregon Running, Eugene?, Half tights/half calves, Flagstaff, Eurocross, USATF road race, Blacksburg???), Ask us a question!, New Recruits, Having teammates leave, TME as a thanksgiving winterTin Talk is brought to you by Pillar Performance. To maximize your performance, recovery, and sleep habits check them out at https://thefeed.com/collections/pillar-performance and use code 'TINTALK' for 15% off.As always, let us know how we did in the comments, shoot us a question, or just tell us how you're doing.Follow Sam: https://www.instagram.com/par_sam_sons/Follow Joey: https://www.instagram.com/joeyberriatua/

Immunotherapy Response in Primary vs Metastatic Pancreatic Cancer

Oncotarget

Play Episode Listen Later Nov 16, 2023 5:23

Pancreatic ductal adenocarcinoma (PDA), a common type of pancreatic cancer, has proven to be largely resistant to immunotherapy, a treatment that uses the body's immune system to fight cancer. Despite numerous successful pre-clinical trials using sophisticated PDA mouse models, clinical trials have failed to show a significant improvement in survival. In a recent editorial, researchers Brian Diskin, Sarah Schwartz and George Miller from Trinity Health of New England shed light on the complex interplay between the immune system and pancreatic cancer. Their paper was published in Oncotarget on April 24, 2023, and entitled, “The critical immune basis for differential responses to immunotherapy in primary versus metastatic pancreatic cancer.” Tumor Microenvironment and Liver Metastasis: Challenges in Pancreatic Cancer The authors attribute PDA immunotherapy resistance to the unique characteristics of the tumor microenvironment (TME). The TME is often hypoxic and fibrotic, making it inaccessible to immune cells. Furthermore, the immune cells that do infiltrate the TME often have tolerogenic features, meaning they are more likely to tolerate the presence of cancer cells rather than attack them. PDA most commonly metastasizes to the liver, an organ known for its immune tolerance. The liver is home to a diverse array of innate immune populations, including NK cells, Kupfer cells, NKT cells, and double negative T cells. Despite this, the liver is the most common location for metastasis from gastrointestinal cancers. “It is an unfortunate fact that all failed clinical trials assessing immunotherapeutic efficacy were conducted in metastatic PDA, whereas basic preclinical investigations are usually performed in primary PDA using genetically engineered mouse models. We postulated that this dichotomy may explain the gap between preclinical promise and ultimate clinical failure.” Full blog - https://www.oncotarget.org/2023/11/16/immunotherapy-response-in-primary-vs-metastatic-pancreatic-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28373 Correspondence to - George Miller - gedalyamil@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28373 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic cancer, liver metastasis, immunnotherapy About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

soundcloud reddit new england primary pda george miller nk immunotherapy pancreatic cancer kupfer pancreatic metastatic tme trinity health nkt tumor microenvironment altmetric oncotarget

Developing medicines for broad populations of cancer patients, Brett Hall, CSO, Immuneering

Biotech 2050 Podcast

Play Episode Listen Later Nov 15, 2023 41:03

Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Brett talks about his background in the military targeting nuclear missiles prior to becoming a scientist and some of the commonalities between working in the military and pharma/biotech. He shares his thoughts on AI and machine learning in drug development. He talks about Immuneering's disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its pipeline. Finally, he discusses their focus on oncology and providing potential treatments for patients with advanced solid tumors. Biography: Brett Hall, Ph.D. has served as Chief Scientific Officer of Immuneering since November 2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., or BioArkive, a privately held biotechnology services company from January 2019 until December 2021. Prior to joining Imuneering, Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC from July 2015 until May 2018. Dr. Hall served in roles of increasing responsibility with Johnson & Johnson from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant® and Imbruvica® through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July 2014 until July 2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall's career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University, and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children's Research Hospital.

Pelvic Exenteration Surgery Series Episode 2: Anterior compartment tumors

Play Episode Listen Later Oct 26, 2023 27:14

australia uk manchester surgery technical knife tumors pelvic rpa anterior pmid compartment tme dcr royal prince alfred hospital paul sutton surgery series

Pelvic Exenteration Surgery Series Episode 1: Principles of Patient Selection and Surgery

university professor prof castro neurosurgery brain cancer university of michigan developmental biology michigan medical school tme

Play Episode Listen Later Oct 23, 2023 29:07

“魔法子弹”XDC：万变不离其宗的靶向分子

Biotech Bar

Play Episode Listen Later Oct 8, 2023 112:28

"靶向分子+偶联药物”模式（XDC）对于肿瘤的靶向治疗意义重大，与传统化疗的大面积杀伤特性不同，XDC能够精准识别、攻击肿瘤细胞，可使用更少的药物达到更好治疗效果和更低的毒性。XDC由靶向分子、连接体、细胞毒性药物组成，识别肿瘤细胞后内吞进入溶酶体后释放药物，通过诱导微管抑制、DNA损伤引起细胞凋亡，同时也通过旁观者效应杀死周围肿瘤细胞。XDC的优点主要体现在靶向分子上，它不但帮助药物定位，并且所具备的多种特征也用来维持药物稳定和后续释放，比如和受体结合的亲和性和特异性，稳定性，以及是否可以透膜或者结合受体后是否触发内吞等。本期节目，我们会聊一聊偶联药物中负责靶向递送的不同分子形式，包括抗体，多肽，小分子，不同靶向分子形式对比各自有什么优劣势，在筛选和发现阶段用到的技术和面临的技术难点，以及偶连药物的内吞和耐药性。备注：ADC: antibody drug conjugate PDC: peptide drug conjugateSMDC: small molecule drug conjugateMoA: mode of actionPROTAC: proteolysis targeting chimeraTME: tumor microenvironment CMC: chemistry, manufacturing, and controlsMTD: maximum tolerated doseADCC: antibody-dependent cellular cytotoxicity ISAC : immune stimulator antibody conjugate本期人物：钰沐菡，「钰沐菡」平台创始人，「Biotech Bar 」主播旺德福，「Biotech Bar 」联合策划人、常驻嘉宾乔晶博士，国内某top3老牌药企的高级研发人员，乔博士进入工业界后在ADC早研领域有5年的开发经验，专注于从靶点发现到临床候选化合物确定的这个阶段季鑫剑博士，瑞士洛桑联邦理工学院博士后研究员时间线00：01：08 XDC药物靶向分子的亲和性和特异性00：19：48 XDC药物在肿瘤微环境(TME)的驻留时间00：24：44 XDC药物的耐药性00：30：43 TME可以定向进化吗？& TME的冷热00：37：47 XDC药物的内吞和ADCC功能00：42：40 XDC药物的稳定性和代谢00：48：48 小分子做靶向分子：SMDC01：04：59 内吞可以预测吗？01：12：35 单价/多价 & 单靶点/多靶点 XDC01：16：09 糖可以作为XDC的靶向分子吗？01：22：31 XDC药物靶向分子(抗体/多肽)的偶联01：35：48 XDC药物靶向分子(抗体/多肽/小分子)的筛选和发现关于「钰沐菡」：积水为川，聚木成林，金玉汇智，茹古涵今致力于生物医药领域的专业知识分享，方便更多从业者学习交流。你也可以在微信公众号和bilibili同名频道找到我们，那里有很多相关领域的课程资源。

cmc adc pdc isac tme xdc

Prof. Maria Castro of University of Michigan on Brain Cancer

Scientific Sense ®

Play Episode Listen Later Sep 8, 2023 53:19

Scientific Sense ® by Gill Eapen: Prof. Maria Castro is Professor of Neurosurgery, and Professor of Cell and Developmental Biology, at the University of Michigan Medical School. Her research program focuses on epigenetic regulation of cancer progression, uncovering the role of oncometabolites in the brain tumor microenvironment (TME), and the development of new therapies for adult and pediatric gliomas. Please subscribe to this channel: https://www.youtube.com/c/ScientificSense?sub_confirmation=1 --- Send in a voice message: https://podcasters.spotify.com/pod/show/scientificsense/message Support this podcast: https://podcasters.spotify.com/pod/show/scientificsense/support

Interview with Dr. Salma Jabbour: An In-depth Look at the PROSPECT Trial

Caris Molecular Minute Podcast Series

Play Episode Listen Later Aug 9, 2023 21:16

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com/POA-Intro/

trial depth evaluation prospect vice chair chemotherapy clinical research asco radiation oncology faculty development l'arc tme jabbour clinical chief folfox chadi nabhan

001 The Introduction: The Motherhood Experience Pilot Episode